Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with
substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the …

The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clinical development for the
treatment of idiopathic pulmonary fibrosis. To explore its mode of action, nintedanib was …

Based on international collaborative data, interstitial lung disease is now the most frequent
cause of death in systemic sclerosis (SSc), having supplanted renal crisis in that regard …

Background Acetylcysteine has been suggested as a beneficial treatment for idiopathic
pulmonary fibrosis, although data from placebo-controlled studies are lacking. Methods In …

6-min walk distance (6MWD) has recently been shown to be associated with the risk of
mortality in patients with idiopathic pulmonary fibrosis (IPF); however, the independent …

Background Interstitial lung disease (ILD) is a common manifestation of polymyositis (PM),
dermatomyositis (DM), and clinically amyopathic dermatomyositis (CADM); however, little is …

Summary Introduction Interstitial lung diseases (ILDs) form a heterogeneous group of
diseases with varying degrees of inflammation and fibrosis. Epidemiological data based on …

Purpose To determine the accuracy of computed tomography (CT) in identifying the
histopathologic usual interstitial pneumonia (UIP) pattern in rheumatoid arthritis–associated …

BACKGROUND Pleuroparenchymal fibroelastosis (PPFE) is a rare form of interstitial
pneumonia and sometimes coexists with a histologic usual interstitial pneumonia (UIP) …

Objectives Biological therapy represents important advances in alleviating rheumatoid
arthritis (RA), but the effect on interstitial lung disease (ILD) has been controversial. The …